[1] HEATH PT. Status of vaccine research and development of vaccines for GBS[J]. Vaccine, 2016, 34(26): 2876. doi: 10.1016/j.vaccine.2015.12.072
[2] RUSSELL NJ, SEALE AC, O'DRISCOLL M, et al. Maternal colonization with Group B Streptococcus and serotype distribution worldwide: systematic review and meta-analyses[J]. Clin Infect Dis, 2017, 65(suppl 2): S100.
[3] GIZACHEW M, TIRUNEH M, MOGES F, et al. Streptococcus agalactiae maternal colonization, antibiotic resistance and serotype profiles in Africa: a meta-analysis[J]. Ann Clin Microbiol Antimicrob, 2019, 18(1): 14. doi: 10.1186/s12941-019-0313-1
[4] PUOPOLO KM, LYNFIELD R, CUMMINGS JJ. Management of infants at risk for Group B Streptococcal disease[J]. Pediatrics, 2019, 144(2): e20191881. doi: 10.1542/peds.2019-1881
[5] HUANG J, LIN XZ, ZHU Y, et al. Epidemiology of group B streptococcal infection in pregnant women and diseased infants in mainland China[J]. Pediatr Neonatol, 2019, 60(5): 487. doi: 10.1016/j.pedneo.2019.07.001
[6] NANDURI SA, PETIT S, SMELSER C, et al. Epidemiology of Invasive early-onset and late-onset Group B Streptococcal disease in the United States, 2006 to 2015: multistate laboratory and population-based surveillance[J]. JAMA Pediatr, 2019, 173(3): 224. doi: 10.1001/jamapediatrics.2018.4826
[7] CEZARINO BN, YAMAMOTO L, DEL NEGRO GM, et al. Diagnosis of neonatal Group B Streptococcus sepsis by nested-PCR of residual urine samples[J]. Braz J Microbiol, 2008, 39(1): 21. doi: 10.1590/S1517-83822008000100005
[8] SHABAYEK S, SPELLERBERG B. Group B Streptococcal colonization, molecular characteristics, and epidemiology[J]. Front Microbiol, 2018, 9: 437. doi: 10.3389/fmicb.2018.00437
[9] VERANI JR, MCGEE L, SCHRAG SJ. Prenvention of perinatal Group B Streptococcal disease-revised guidelines from CDC, 2010[J]. MMWR Recomm Rep, 2010, 59(RR 10): 1.
[10] SCHRAG SJ, VERANI JR. Intrapartum antibiotic prophylaxis for the prevention of perinatal group B Streptococcal disease: experience in the United States and implications for a potential group B streptococcal vaccine[J]. Vaccine, 2013, 31(Suppl 4): D20.
[11] KWATRA G, CUNNINGTON MC, MERRALL E, et al. Prevalence of maternal raniantion with group B Streptococcus: a systematic review and meta-analysis[J]. Lancet Infect Dis, 2016, 16(9): 1076. doi: 10.1016/S1473-3099(16)30055-X
[12] DING Y, WANG Y, HSIA Y, et al. Systematic review and meta-analyses of incidence for group B streptococcus disease in infants and antimicrobial resistance, China[J]. Emerg Infect Dis, 2020, 26(11): 2651. doi: 10.3201/eid2611.181414
[13] LANG S, PALMER M. Characterization of Streptococcus agalactiae CAMP factor as a pore-forming toxin[J]. J Biol Chem, 2003, 278(40): 38167. doi: 10.1074/jbc.M303544200
[14] JIN T, BREFO-MENSAH E, FAN W, et al. Crystal structure of the Streptococcus agalactiae CAMP factor provides insights into its membrane-permeabilizing activity[J]. J Biol Chem, 2018, 293(30): 11867. doi: 10.1074/jbc.RA118.002336
[15] GOUDARZI G, GHAFARZADEH M, SHAKIB P, et al. Culture and real-time PCR based maternal screening and antibiotic susceptibility for group B Streptococcus: an ranian experience[J]. Glob J Health Sci, 2015, 7(6): 233.
[16] TANAKA K, IWASHITA M, MATSUSHIMA M, et al. Intrapartum group B Streptococcus screening using real-time polymerase chain reaction in Japanese population[J]. J Matern Fetal Neonatal Med, 2016, 29(1): 130. doi: 10.3109/14767058.2014.989496
[17] HASSAN AA, AKINEDEN O, LAMMLER C, et al. Molecular characterization of phenotypically CAMP-negative Streptococcus agalactiae isolated from bovine mastitis[J]. J Vet Med B Infect Dis Vet Public Health, 2002, 49(5): 257. doi: 10.1046/j.1439-0450.2002.00553.x
[18] RAJAGOPAL L. Understanding the regulation of Group B Streptococcal virulence factors[J]. Future Microbiol, 2009, 4(2): 201.
[19] HENSLER ME, QUACH D, HSIEH CJ, et al. CAMP factor is not essential for systemic virulence of Group B Streptococcus[J]. Microb Pathog, 2008, 44(1): 84. doi: 10.1016/j.micpath.2007.08.005